Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ, Jouary T, Dréno B, Asselineau J, Gutzmer R, Hauschild A, Leccia MT, Landthaler M, Garbe C, Sassolas B, Herbst RA, Guillot B, Chene G, Pehamberger H. Grob JJ, et al. Among authors: sassolas b. Eur J Cancer. 2013 Jan;49(1):166-74. doi: 10.1016/j.ejca.2012.07.018. Epub 2012 Sep 10. Eur J Cancer. 2013. PMID: 22975216 Clinical Trial.
Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ, Dreno B, de la Salmonière P, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ. Grob JJ, et al. Among authors: sassolas b. Lancet. 1998 Jun 27;351(9120):1905-10. doi: 10.1016/s0140-6736(97)12445-x. Lancet. 1998. PMID: 9654256 Clinical Trial.
Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study.
Jouary T, Leyral C, Dreno B, Doussau A, Sassolas B, Beylot-Barry M, Renaud-Vilmer C, Guillot B, Bernard P, Lok C, Bedane C, Cambazard F, Misery L, Estève E, Dalac S, Machet L, Grange F, Young P, Granel-Brocard F, Truchetet F, Vergier B, Delaunay MM, Grob JJ; Groupe de Cancérologie Cutanée of the Société Française de Dermatologie. Jouary T, et al. Among authors: sassolas b. Ann Oncol. 2012 Apr;23(4):1074-80. doi: 10.1093/annonc/mdr318. Epub 2011 Jul 12. Ann Oncol. 2012. PMID: 21750118 Free article. Clinical Trial.
Cutaneous malignant melanoma and neurofibromatosis type 1.
Guillot B, Dalac S, Delaunay M, Baccard M, Chevrant-Breton J, Dereure O, Machet L, Sassolas B, Zeller J, Bernard P, Bedane C, Wolkenstein P; French Group of Cutaneous Oncology. Guillot B, et al. Among authors: sassolas b. Melanoma Res. 2004 Apr;14(2):159-63. doi: 10.1097/00008390-200404000-00014. Melanoma Res. 2004. PMID: 15057048
Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans.
Martin L, Piette F, Blanc P, Mortier L, Avril MF, Delaunay MM, Dréno B, Granel F, Mantoux F, Aubin F, Sassolas B, Adamski H, Dalac S, Pauwels C, Dompmartin A, Lok C, Estève E, Guillot B; French Group for Cutaneous Oncology. Martin L, et al. Among authors: sassolas b. Br J Dermatol. 2005 Nov;153(5):932-6. doi: 10.1111/j.1365-2133.2005.06823.x. Br J Dermatol. 2005. PMID: 16225602
Cutaneous melanoma in patients treated with tumour necrosis factor inhibitors: a retrospective series of 15 patients.
Chabbert C, Adamski H, Guillet G, Sassolas B, Misery L, Perrinaud A, Machet L, Quereux G, Esteve E, Solau-Gervais E, Saraux A, Polard E, Lesimple T, Le Gall F, Dreno B, Dupuy A. Chabbert C, et al. Among authors: sassolas b. J Eur Acad Dermatol Venereol. 2014 Nov;28(11):1540-4. doi: 10.1111/jdv.12347. Epub 2013 Dec 13. J Eur Acad Dermatol Venereol. 2014. PMID: 24329560
182 results